CASC3 and acute lymphoblastic leukemia: The combination of BTZ, rituximab, and a pediatric-inspired ALL regimen was seen to be active and well tolerated in de novo CD20+ Philadelphia-negative precursor B-ALL (Hunger and Mullighan, 2015[60]).